| answer text |
<p>Department ministers and officials regularly meet with a range of organisations,
with an interest in securing patient access to new cancer medicines. The National
Institute for Health and Care Excellence (NICE) is the body that develops authoritative,
evidence-based guidance for the National Health Service on whether new licensed medicines
should be routinely funded by the NHS, based on an assessment of their costs and benefits,
including medicines for myeloma. The NICE aims to publish guidance on all new medicines
close to the point of licensing wherever possible, and has recommended many cancer
medicines for NHS use that are now available to NHS patients, including through the
Cancer Drugs Fund.</p>
|
 |
